Edward Tobinick

Edward Lewis Tobinick is an American physician currently in full-time private practice in Los Angeles, California and he is an Assistant Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA.[1] Dr. Tobinick is co-author of the recent case report documenting rapid clinical improvement in a patient with Alzheimer's disease following perispinal administration of etanercept[2] which has been received with considerable interest.[1][3]. Wyeth in collaboration with the University of Southampton has, as of January 2011, begun enrollment into a randomized, placebo-controlled clinical trial of etanercept for patients with Alzheimer's disease. Also being trialed currently, in a multi-center study, is the use of epidural etanercept for sciatica (U.S. patent 6,419,944 issued to Tobinick July 2002), for which favorable randomized, placebo-controlled clinical data from Walter Reed Army Medical Center were published in 2009 (Anesthesiology. 2009 May;110(5):1116-26).

Tobinick has been issued patents for methods of perispinal administration, of certain recombinant DNA-derived (biologic) therapeutics including the TNF receptor fusion protein etanercept, for the treatment of certain neurologic disorders with widespread unmet medical need, including Alzheimer's disease; pain due to cancer metastasis to bone; severe, intractable, intervertebral disc-related pain and radiculopathy (including sciatica); and myasthenia gravis.[4] In addition, he originated the concept of the potential utility of etanercept, alone or in combination with oseltamivir for treatment of influenza (U.S. patent 6,419,934, filed September 5, 2000 [1]). For these novel treatment methods he has been issued multiple U.S. patents, including 6,015,557 (Tumor necrosis factor antagonists for the treatment of neurological disorders) [2]; 6,177,077 [3]; 6,419,934 [4]; and 6,982,089 [5]. In general, his concepts represent emerging therapeutic strategies supported by small pilot studies and expert reviews. (see Publications and References).[5]

Tobinick earned his M.D. from the UC San Diego School of Medicine in 1977.

Publications

References

  1. ^ a b UCLA Headlines Jan. 11, 2008 / UCLA Newsroom
  2. ^ Journal of Neuroinflammation | Full text | Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration
  3. ^ Journal of Neuroinflammation | Full text | Perispinal etanercept: Potential as an Alzheimer therapeutic
  4. ^ United States Patent 6,423,321
  5. ^ Tobinick's private practice

External links